CSF2 and breast carcinoma: performed a proof-of-principle trial where they supplemented RT with subcutaneous GM-CSF, a cytokine that promotes dendritic cell differentiation and expansion, in patients with metastatic tumors including breast cancer, bladder cancer, and eccrine cancer (51, 62).